Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Vaccine maker stocks fall as Trump chooses RFK Jr. to lead HHS
Shares of vaccine makers fell as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Services. Health policy experts have said a second Trump term could allow Kennedy to elevate anti-vaccine rhetoric.
Vaccine makers fall after Trump nominates RFK to head HHS
BioNTech (BNTX), Pfizer (PFE), Novavax (NVAX), Vaxcyte (PCVX) and GSK (GSK) moved lower at the end of the trading day following reports that President-elect Donald Trump Donald Trump would nominate noted vaccine skeptic Robert F.
Trump Picks Vaccine Skeptic Robert F. Kennedy Jr. to Lead Health & Human Services
In a move guaranteed to alarm many, President-elect Donald Trump has chosen Robert F. Kennedy Jr., a vocal opponent of vaccines and other tenets of mainstream health care, to head the massive U.S. Department of Health and Human Services (HHS).
Trump taps Robert F. Kennedy Jr., vaccine skeptic, to lead health department
The nearly $2 trillion agency administers health-insurance programs for millions of Americans, approves medications and oversees vaccine safety.
Europe's vaccine makers fall as Trump picks RFK Jr to lead top US health agency
Shares in European vaccine-makers fell in early trade on Friday after U.S. President-elect Donald Trump said he had selected Robert F. Kennedy Jr., who has previously spread misinformation on vaccines,
Trump picks RFK Jr. for HHS Secretary, Democratic Senators call him a ‘danger’ to public health
Celine Dion Rules Runway With Glittering Performance at Hits at Elie Saab Fashion Show in Riyadh Trump transition live coverage: Donald Trump chooses Robert F. Kennedy Jr. to lead HHS 14 of the Most Baffling Mysteries About the Universe The world’s tallest teenager,
Trump Speaks on RFK Jr. Nomination: 'Nobody's Going to Do it Like You'
President-elect Donald Trump praised Robert F. Kennedy Jr. while speaking at Mar-a-Lago on Thursday night, saying that "nobody's going to be able to do it like you." Trump nominated Kennedy for Secretary of Health and Human Services earlier in the day,
Pharmabiz
34m
BioNTech to acquire clinical-stage biotech company, Biotheus to boost oncology strategy
BioNTech
SE and Biotheus (Biotheus) announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development ...
1d
on MSN
BioNTech buys China's Biotheus to support oncology strategy
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain ...
Investor's Business Daily on MSN
13h
BioNTech Stock Got A IBD RS Rating Lift
How Much Money To Invest Now. Is BioNTech Stock A Buy? BioNTech stock is building a consolidation with a 131.49 buy point.
GlobalData on MSN
22h
BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
FierceBiotech
2d
BioNTech pays $800M to take control of potential Keytruda killer
BioNTech
is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus ...
14h
The Analyst Landscape: 17 Takes On BioNTech
Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
STAT
1d
BioNTech acquires its Chinese cancer drug partner
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
AOL
1d
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
On Wednesday,
BioNTech
SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
BioPharma Dive
1d
BioNTech to buy Biotheus, gaining control of cancer bispecific
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
16h
Strategic Acquisition and Oncology Focus Justify BioNTech’s Buy Rating
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
3d
BioNTech (NASDAQ:BNTX) Raised to “Buy” at The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Trade
BNTX
Feedback